Stryker Corporation (SYK) is a leading medical devices business based in the US. It opened the day at $275.49 after a previous close of $276.11. During the day the price has varied from a low of $272.48 to a high of $275.73. The latest price was $273.03 (25 minute delay). Stryker Corporation is listed on the NYSE and employs 43,000 staff. All prices are listed in US Dollars.
Best for
US shares
Best for
Low-cost
Best for
Beginners
Best for
Range of stock exchanges
Since the stock market crash that started in February 2020, Stryker Corporation's share price has had significant positive movement.
Its last market close was $273.03, which is 17.85% up on its pre-crash value of $224.3 and 119.23% up on the lowest point reached during the March 2020 crash when the shares fell as low as $124.54.
If you had bought $1,000 worth of Stryker Corporation shares at the start of February 2020, those shares would have been worth $598.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,291.43.
| Open | $275.49 |
|---|---|
| High | $275.73 |
| Low | $272.48 |
| Close | $273.03 |
| Previous close | $276.11 |
| Change | $-3.08 |
| Change % | -1.1155% |
| Volume | 2,824,306 |
| 52-week range | $194.5988 - $281.16 |
|---|---|
| 50-day moving average | $269.4214 |
| 200-day moving average | $257.1084 |
| Wall St. target price | $287.67 |
| PE ratio | 50.033 |
| Dividend yield | $2.465 (0.89%) |
| Earnings per share (TTM) | $5.457 |
Other fees apply. Your capital is at risk.
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | No minimum | £4.47 £998.71 total |
Capital at risk |
|
£0 | $50 | £4.97 £999.21 total |
Capital at risk |
 |
£0 | £0.01 | £1.44 £995.68 total |
Capital at risk |
 |
£0 | £50 | £4.99 £999.22 total |
Capital at risk |
|
£0 | £1 | £21.91 £1,016.15 total |
Capital at risk |
 |
£9.99 per month | No minimum | £22.92 £1,017.16 total |
Capital at risk |
 |
£0 | No minimum | £9.94 £1,004.18 total |
Capital at risk |
 |
£36 per year | £20 | £21.94 £1,016.18 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $273.03
| 1 week (2021-09-09) | -1.40% |
|---|---|
| 1 month (2021-08-19) | 3.30% |
| 3 months (2021-06-18) | 7.11% |
| 6 months (2021-03-19) | 18.71% |
| 1 year (2020-09-18) | 32.29% |
|---|---|
| 2 years (2019-09-19) | 23.52% |
| 3 years (2018-09-19) | 57.34% |
| 5 years (2016-09-19) | 138.62% |
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Stryker Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, Stryker Corporation shares trade at around 50x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Stryker Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9927. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Stryker Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Stryker Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $4.6 billion (£3.4 billion).
The EBITDA is a measure of a Stryker Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.2 billion |
|---|---|
| Operating margin TTM | 22.69% |
| Gross profit TTM | $9.2 billion |
| Return on assets TTM | 7.07% |
| Return on equity TTM | 15.68% |
| Profit margin | 12.82% |
| Book value | $36.648 |
| Market capitalisation | $103 billion |
TTM: trailing 12 months
There are currently 3.4 million Stryker Corporation shares held short by investors – that's known as the "short interest". This figure is 20.1% up from 2.8 million last month.
There are a few different ways that this level of interest in shorting Stryker Corporation shares can be evaluated.
Stryker Corporation's "short interest ratio" (SIR) is the quantity of Stryker Corporation shares currently shorted divided by the average quantity of Stryker Corporation shares traded daily (recently around 1.2 million). Stryker Corporation's SIR currently stands at 2.75. In other words for every 100,000 Stryker Corporation shares traded daily on the market, roughly 2750 shares are currently held short.
However Stryker Corporation's short interest can also be evaluated against the total number of Stryker Corporation shares, or, against the total number of tradable Stryker Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Stryker Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Stryker Corporation shares in existence, roughly 10 shares are currently held short) or 0.0102% of the tradable shares (for every 100,000 tradable Stryker Corporation shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Stryker Corporation.
Find out more about how you can short Stryker Corporation stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Stryker Corporation.
Stryker Corporation's total ESG risk: 33.93
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Stryker Corporation's overall score of 33.93 (as at 12/31/2018) is pretty weak – landing it in it in the 71st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Stryker Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Stryker Corporation's environmental score: 3.06/100
Stryker Corporation's environmental score of 3.06 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Stryker Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Stryker Corporation's social score: 14.68/100
Stryker Corporation's social score of 14.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Stryker Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Stryker Corporation's governance score: 8.19/100
Stryker Corporation's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Stryker Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Stryker Corporation's controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Stryker Corporation scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Stryker Corporation hasn't always managed to keep its nose clean.
Stryker Corporation was last rated for ESG on: 2019-01-01.
| Total ESG score | 33.93 |
|---|---|
| Total ESG percentile | 70.66 |
| Environmental score | 3.06 |
| Environmental score percentile | 1 |
| Social score | 14.68 |
| Social score percentile | 1 |
| Governance score | 8.19 |
| Governance score percentile | 1 |
| Level of controversy | 3 |
Dividend yield: 0.89% of stock value
Forward annual dividend yield: 0.91% of stock value
Dividend payout ratio: 27.6% of net profits
Stryker Corporation has recently paid out dividends equivalent to 0.89% of its share value annually.
Stryker Corporation has paid out, on average, around 27.6% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.91% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 0.91% return on their shares, in the form of dividend payments. In Stryker Corporation's case, that would currently equate to about $2.465 per share.
While Stryker Corporation's payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.
Stryker Corporation's most recent dividend payout was on 28 October 2021. The latest dividend was paid out to all shareholders who bought their shares by 28 September 2021 (the "ex-dividend date").
Stryker Corporation's shares were split on a 2:1 basis on 16 May 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Stryker Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Stryker Corporation shares which in turn could have impacted Stryker Corporation's share price.
Over the last 12 months, Stryker Corporation's shares have ranged in value from as little as $194.5988 up to $281.16. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Stryker Corporation's is 0.9869. This would suggest that Stryker Corporation's shares are less volatile than average (for this exchange).
Subscribe to trending stock alerts for a chance to win
Ever wondered how to buy shares in IronNet? We explain how and compare a range of providers that can give you access to many brands, including IronNet.
Ever wondered how to buy shares in Rocket Lab USA? We explain how and compare a range of providers that can give you access to many brands, including Rocket Lab USA.
Ever wondered how to buy shares in Camber Energy? We explain how and compare a range of providers that can give you access to many brands, including Camber Energy.
Ever wondered how to buy shares in Aterian? We explain how and compare a range of providers that can give you access to many brands, including Aterian.
Ever wondered how to buy shares in eFFECTOR Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including eFFECTOR Therapeutics.
Ever wondered how to buy shares in Santhera Pharmaceuticals Holding AG? We explain how and compare a range of providers that can give you access to many brands, including Santhera Pharmaceuticals Holding AG.
Ever wondered how to buy shares in Basilea Pharmaceutica? We explain how and compare a range of providers that can give you access to many brands, including Basilea Pharmaceutica.
Ever wondered how to buy shares in AB Science S.A.? We explain how and compare a range of providers that can give you access to many brands, including AB Science.
Ever wondered how to buy shares in Acacia Pharma Group? We explain how and compare a range of providers that can give you access to many brands, including Acacia Pharma Group.
Ever wondered how to buy shares in Blue Water Acquisition? We explain how and compare a range of providers that can give you access to many brands, including Blue Water Acquisition.
